US 9987241
Enzyme conjugate and prodrug cancer therapy
granted A61KA61K31/198A61K31/436
Quick answer
US patent 9987241 (Enzyme conjugate and prodrug cancer therapy) held by The Board of Regents of the University of Oklahoma expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Oklahoma
- Grant date
- Tue Jun 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K31/198, A61K31/436, A61K31/664, A61K31/675